1. Home
  2. PRO vs ANAB Comparison

PRO vs ANAB Comparison

Compare PRO & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRO
  • ANAB
  • Stock Information
  • Founded
  • PRO 1985
  • ANAB 2005
  • Country
  • PRO United States
  • ANAB United States
  • Employees
  • PRO N/A
  • ANAB N/A
  • Industry
  • PRO EDP Services
  • ANAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • PRO Technology
  • ANAB Health Care
  • Exchange
  • PRO Nasdaq
  • ANAB Nasdaq
  • Market Cap
  • PRO 898.3M
  • ANAB 759.5M
  • IPO Year
  • PRO 2007
  • ANAB 2017
  • Fundamental
  • Price
  • PRO $17.89
  • ANAB $20.70
  • Analyst Decision
  • PRO Strong Buy
  • ANAB Buy
  • Analyst Count
  • PRO 10
  • ANAB 9
  • Target Price
  • PRO $31.10
  • ANAB $34.86
  • AVG Volume (30 Days)
  • PRO 615.5K
  • ANAB 789.1K
  • Earning Date
  • PRO 05-01-2025
  • ANAB 05-08-2025
  • Dividend Yield
  • PRO N/A
  • ANAB N/A
  • EPS Growth
  • PRO N/A
  • ANAB N/A
  • EPS
  • PRO N/A
  • ANAB N/A
  • Revenue
  • PRO $330,372,000.00
  • ANAB $91,280,000.00
  • Revenue This Year
  • PRO $10.12
  • ANAB N/A
  • Revenue Next Year
  • PRO $10.10
  • ANAB $37.76
  • P/E Ratio
  • PRO N/A
  • ANAB N/A
  • Revenue Growth
  • PRO 8.78
  • ANAB 432.03
  • 52 Week Low
  • PRO $14.81
  • ANAB $12.21
  • 52 Week High
  • PRO $34.54
  • ANAB $41.31
  • Technical
  • Relative Strength Index (RSI)
  • PRO 48.61
  • ANAB 61.93
  • Support Level
  • PRO $15.22
  • ANAB $19.57
  • Resistance Level
  • PRO $17.74
  • ANAB $22.29
  • Average True Range (ATR)
  • PRO 0.89
  • ANAB 1.46
  • MACD
  • PRO 0.35
  • ANAB 0.27
  • Stochastic Oscillator
  • PRO 99.68
  • ANAB 76.92

About PRO PROS Holdings Inc.

Pros Holdings Inc. is a provider of cloud-based revenue and profit realization software solutions to business-to-business and business-to-consumer companies. Its solutions assist customers in growing revenue, modernizing business processes, and supporting profitability by leveraging prescriptive analytics and data science-based decision-making technology. The company's solutions enable buyers to move fluidly across its customers' direct sales, partner, online, mobile, and emerging channels with personalized experiences. The firm generates revenue in the United States, Europe, Africa, Asia-Pacific, and Middle East regions.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: